Marshall Edwards, Inc. Announces Pricing of Initial Public Offering of 2,080,000 of Common Stock Units at $7.50 Per Unit
December 18 2003 - 9:13AM
PR Newswire (US)
Marshall Edwards, Inc. Announces Pricing of Initial Public Offering
of 2,080,000 of Common Stock Units at $7.50 Per Unit WASHINGTON,
Dec. 18 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. today
announced the pricing of its initial U.S. public offering (IPO) of
2,080,000 common stock units at a price of $7.50 per unit. Each
common stock unit consists of one share of common stock and one
warrant to purchase a share of common stock at an exercise price of
$9.00 per share. The common stock and the warrants will trade
separately from one another and are expected to begin trading on
the Nasdaq National Market today. The common stock will be listed
under the symbol "MSHL" and the warrants will be listed under the
symbol "MSHLW." Up to 1,500,000 common stock units are being sold
through a directed share subscription program to U.S. holders of
Novogen's (NASDAQ:NVGN) ordinary shares and American Depository
Receipts (ADRs) and U.S. holders of Marshall Edwards, Inc.'s common
stock (other than Novogen), who owned their shares or ADRs as of
October 20, 2003. 580,000 common stock units plus any units not
subscribed for in the directed share subscription program, are
being sold to the underwriter for sale to the public. The
underwriter has been granted by Marshall Edwards, Inc. the right to
purchase up to an additional 312,000 common stock units if it
exercises its over-allotment option in full within the next 30
days. Marshall Edwards, Inc. intends to use the net proceeds from
the offering to conduct ongoing human clinical trials of
phenoxodiol, its anti-cancer drug candidate, as well as for general
corporate purposes. Janney Montgomery Scott LLC is the underwriter
for the underwritten portion of the offering and is dealer manager
for the directed share subscription program. Copies of the final
prospectus relating to this offering may be obtained by calling
Innisfree M&A Inc. at 877-456-3510 or Janney Montgomery Scott
LLC at 410-822-1181. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state. About Marshall Edwards, Inc. Marshall Edwards, Inc. is a
pharmaceutical company focused on the development and
commercialization of therapies to treat patients with various forms
of cancer. Marshall Edwards, Inc. is currently listed on the London
Stock Exchange's Alternative Investment Market under the symbol
MSH. DATASOURCE: Marshall Edwards, Inc. CONTACT: US-Australia: Mr.
Christopher Naughton, President and CEO of Marshall Edwards, Inc.,
+ 61.2.9878 0088
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024